ATTR-ACT Authors’ Conclusions1
In patients with ATTR-CM, tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations compared with placebo
Tafamidis treatment also significantly reduced the decline in functional capacity and quality of life
These findings indicate that tafamidis is an effective therapy for patients with transthyretin amyloid cardiomyopathy
ATTR-ACT: Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy; ATTR-CM: transthyretin amyloid cardiomyopathy.
